Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) is under legal investigation and is back in the news. The legal investigation is relating to the proposed merger with Aadi Bioscience, Inc. According to the agreement, shareholders of Aerpio Pharmaceuticals Inc are expected to own 14.7% of the combined company after the closing of the concurrent PIPE financing transaction. An investigation is initiated to determine if Aerpio Pharmaceuticals, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the company.
DiDi Global Inc – ADR (NYSE: DIDI) also under investigation
DiDi Global Inc – ADR (NYSE: DIDI) is also under investigation. A class-action lawsuit has been filed on behalf of investors of the company. According to reports, the case is presented in the lead plaintiff stage. The investor protection team of the Thornton Law Firm is fighting the case on behalf of investors. The team from the law firm has alerted investors that the class action lawsuit has been filed on behalf of investors of DiDi Global Inc.
ContextLogic Inc (NASDAQ: WISH) is under the legal scanner
ContextLogic Inc (NASDAQ: WISH) has come under the legal scanner of Pomerantz LLP. The law firm pioneered the field of securities class actions and is investigating claims on behalf of the company’s investors. Pomerantz LLP initiated the investigation to learn if the company or certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Ocugen Inc (NASDAQ: OCGN) facing legal trouble
Ocugen Inc (NASDAQ: OCGN) is facing legal trouble. Labaton Sucharow, an award-winning shareholder rights law firm, is investigating claims made by stakeholders of the company. The law firm has initiated an investigation to determine if the potential securities violations and breach of fiduciary duty claims made against the company are true.
Ocugen Inc had initially proposed to apply for emergency use authorization of COVID-19 vaccine candidate, Covaxin. However, the company later announced that it would no longer go ahead as planned. As a result, Ocugen Inc made it official that the company would instead obtain full approval.